Shilpa Medicare's Q1 FY 2025-26 Quarterly Results

Result Summary

• Shilpa Medicare Ltd reported a 11.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.6%.
• Its expenses for the quarter were up by 1.9% QoQ and 2.9% YoY.
• The net profit increased 91.4% QoQ and increased 233.5% YoY.
• The earnings per share (EPS) of Shilpa Medicare Ltd stood at 4.8 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Shilpa Medicare Ltd is a company operating in the pharmaceutical industry, primarily engaged in the development and manufacturing of high-quality generic pharmaceutical products. The company is known for its focus on oncology drugs, which are used in cancer treatment, along with other therapeutic segments. Shilpa Medicare has a strong presence in both domestic and international markets, supplying its products to various countries. The company is committed to research and development, constantly striving to innovate and expand its product portfolio. Recent developments in the company may include expansion of its manufacturing capabilities or new product launches, although specific details are not provided in the data.

Revenue

In the first quarter of the fiscal year 2026 (Q1FY26), Shilpa Medicare Ltd reported a total income of ₹327.84 crores. This represents an increase of 11.4% compared to the previous quarter (Q4FY25), where the total income was ₹294.19 crores. Year-over-year (YoY), the total income grew by 8.6% from ₹301.95 crores in Q1FY25. This upward trend in revenue suggests the company has experienced growth in its sales or other income sources over the past year and quarter. The positive QoQ and YoY growth in total income highlights the company's ability to enhance its revenue generation capabilities within competitive market conditions.

Profitability

Shilpa Medicare Ltd's profitability metrics for Q1FY26 show significant improvement. The company reported a Profit Before Tax (PBT) of ₹50.31 crores, which is an 80.6% increase from ₹27.85 crores in Q4FY25 and a 56.2% increase from ₹32.20 crores in Q1FY25. The Profit After Tax (PAT) for Q1FY26 was ₹46.89 crores, showing a substantial rise of 91.4% QoQ from ₹24.50 crores and a dramatic 233.5% YoY increase from ₹14.06 crores. The tax expense for Q1FY26 was ₹2.69 crores, a decrease from both the previous quarter and the same quarter last year. This decline in tax expense, combined with higher profits, contributed to the increased net profitability. The Earnings Per Share (EPS) also saw a notable increase, reaching ₹4.80 in Q1FY26, up from ₹2.80 in Q4FY25 and ₹1.50 in Q1FY25, reflecting the enhanced earnings capacity per share for the shareholders.

Operating Metrics

The total expenses for Shilpa Medicare Ltd in Q1FY26 were ₹277.52 crores, marking a 1.9% increase from ₹272.46 crores in Q4FY25, and a 2.9% increase from ₹269.76 crores in Q1FY25. Despite the rise in expenses, the company's income growth outpaced the increase in expenses, leading to improved profitability. The control over expense growth while enhancing revenue demonstrates efficient operational management. The reporting period's financial data indicates effective cost management strategies, as evidenced by the smaller percentage increase in expenses compared to income. This operational efficiency is reflected in the significant rise in profit margins, contributing to a healthier financial performance.